Possible explanations were as follows: (1) Fondaparinux did not bind to platelet factor 4 and reduced the risk of thrombocytopenia; meanwhile, it also did not affect prothrombin time or activated partial thromboplastin time (22, 23). The gene discussed is F2; the disease is Thrombocytopenia.